Valuation: Royalty Pharma plc

Market Cap 26.06B 22.87B 21.5B 19.66B 36.73B 2,496B 37B 258B 100B 1,273B 97.85B 95.71B 4,126B P/E 2026 *
23.7x
P/E 2027 * 16.6x
Enterprise Value 35.17B 30.87B 29.02B 26.53B 49.57B 3,369B 49.94B 349B 135B 1,718B 132B 129B 5,569B EV / Sales 2026 *
10x
EV / Sales 2027 * 9.26x
Free-Float
72.41%
Yield 2026 *
1.73%
Yield 2027 * 1.82%
1 day-0.83%
1 week-0.56%
Current month-5.32%
1 month-5.20%
3 months+5.04%
6 months+27.47%
Current year+50.47%
1 week 57.82
Extreme 57.82
59.18
1 month 57.75
Extreme 57.75
64.38
Current year 38.29
Extreme 38.29
64.38
1 year 34.63
Extreme 34.63
64.38
3 years 24.05
Extreme 24.05
64.38
5 years 24.05
Extreme 24.05
64.38
10 years 24.05
Extreme 24.05
64.38
Manager TitleAgeSince
Chief Executive Officer 62 01/01/1996
Director of Finance/CFO 44 01/01/2010
Chief Tech/Sci/R&D Officer - 21/09/2023
Director TitleAgeSince
Chairman 62 01/04/2020
Director/Board Member 68 11/02/2020
Director/Board Member 63 16/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 A Don

Executive/Senior Manager

-16,800 0.0038%
8/13/26 A Sell

Chief Financial Officer

-11,002 0.0025%
8/7/26 A Don

Chief Financial Officer

-18,500 0.0754%
Change 5-day change 1-year change 3-year change Capi.($)
-0.69%-0.56%+60.43%+118.49% 26.06B
-1.46%+1.52%+54.64%+109.15% 1,043B
-0.75%+0.19%+51.65%+67.09% 649B
-0.41%+0.68%+18.73%+70.90% 469B
-0.25%+0.19%+36.95%+45.54% 355B
+0.98%+2.91%+20.59%+27.14% 270B
-1.91%+2.42%+10.41%+11.04% 262B
-1.24%+7.59%+41.17%+51.73% 222B
-1.40%+1.88%+31.51%+101.06% 189B
-2.53%-7.47%-32.63%-60.41% 175B
Average -0.92%+1.99%+29.35%+54.17% 365.91B
Weighted average by Cap. -0.94%+2.17%+35.97%+65.61%

Financials

2026 *2027 *
Net sales 3.5B 3.08B 2.89B 2.64B 4.94B 336B 4.98B 34.72B 13.46B 171B 13.16B 12.87B 555B 3.81B 3.34B 3.14B 2.87B 5.37B 365B 5.41B 37.74B 14.63B 186B 14.3B 13.99B 603B
Net income 1.47B 1.29B 1.21B 1.11B 2.07B 141B 2.09B 14.58B 5.65B 71.88B 5.53B 5.41B 233B 1.8B 1.58B 1.48B 1.35B 2.53B 172B 2.55B 17.8B 6.9B 87.7B 6.74B 6.6B 284B
Net Debt 9.11B 8B 7.52B 6.87B 12.84B 873B 12.94B 90.28B 35B 445B 34.21B 33.46B 1,443B 9.22B 8.09B 7.61B 6.95B 13B 883B 13.09B 91.37B 35.42B 450B 34.62B 33.86B 1,460B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and over 17 development-stage product candidates.
Employees
100
Date Price Change Volume
23/09/26 $58.11 -0.70% 758,632
22/09/26 $58.52 +0.14% 2,691,703
21/09/26 $58.44 +0.05% 3,231,940
18/09/26 $58.41 -0.88% 7,104,694
17/09/26 $58.93 +0.79% 2,062,552
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
58.52USD
Average target price
65.12USD
Spread / Average Target
+11.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!